MO-PIERIANDX
17.11.2020 17:02:11 CET | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, and Bench International, a leading global executive search firm, jointly announce the appointment of Mark McDonough as Chief Executive Officer (CEO) and member of the Board of Directors of PierianDx, effective immediately. In his new role, McDonough will help fulfill the company’s unique value proposition of enabling precision medicine through its best-in-class variant interpretation knowledgebase, integrated infrastructure, and clinical genomics reporting for both cancer and inherited disease. McDonough succeeds Chairman of the Board and Interim CEO, Joe Boorady, who remains as Chairman of the PierianDx Board of Directors.
“Mark commands a deep understanding of the diagnostics market, and we are delighted to welcome him to the PierianDx family during this exciting time in the company's development,” said Joe Boorady. “Mark will drive company execution on its IVD strategy and solidify its leadership position in the global cancer and hereditary disease diagnostics market.”
Mark McDonough is a global technology business executive with nearly 30 years of experience. His personal mission is to impact change in the field of healthcare in a compassionate yet resolute manner, leading by example. He most recently served as CEO and board member for Immunis.AI, where he secured funding and developed a top flight team within six months to launch a novel noninvasive liquid biopsy immunogenomics assay for prostate cancer patients on ‘active surveillance.’ Prior to this, McDonough served as President, CEO and board member of CombiMatrix from 2012 through 2018, orchestrating its sale to Invitae in November 2017. Under his leadership, CombiMatrix experienced 14 consecutive quarters of record growth. Earlier in his career, he served in various sales leadership roles within the clinical laboratory industry and developed his leadership skills as a Navigator and Communications Officer in the US Navy.
“An established, respected and trusted leader in the genomics industry, Mark is the perfect CEO for PierianDx,” said DeeDee DeMan, Chairman and CEO of Bench International. “He has a remarkable track record of developing teams, fundraising, and directing corporate strategy and growth.”
"I am excited to join PierianDx and lead this talented team committed to delivering tools to our partners and customers that enable precision medicine adoption at scale,” said Mark McDonough. “We believe advanced genomic testing should be democratized and available to all at the highest quality and lowest cost. I look forward to helping propel the company as we expand our market leadership and serve more patients through our partners and customers."
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. For more information visit www.pieriandx.com .
About Bench International
Bench International is the oldest woman-founded executive search firm serving the Life Science and Healthcare sectors. The firm is also one of the most renowned experts in diversity recruitment at the board and executive level, as well as in R&D leadership. Bench’s scorecard reflects over $150 billion in successful client exits, a 98% project completion record, with a 75% retention for five or more years. 33% of all leaders placed in Bench’s 45+ year history have been gender and ethnically diverse. With headquarters in San Diego, California, and satellite offices in Los Angeles, New York, Boston, the United Kingdom and Switzerland, Bench is One Global Team, No Borders, No Boundaries and One Global Budget, thus mitigating internally competitive offices. For more information visit www.benchinternational.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005961/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Announces Novel Quantum Error Correction Approach Toward Fault-Tolerant Quantum Computing9.6.2026 09:00:00 CEST | Press release
New approach delivers cutting edge performance, while significantly reducing hardware complexity IQM Quantum Computers, the global leader in superconducting quantum computers, has developed a novel quantum error-correcting code that achieves up to three orders of magnitude lower logical error rates than the surface code, also requiring up to eight times fewer physical qubits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609533201/en/ IQM´s breakthrough technology, called barbell codes. Unlike many alternative high-performance quantum error-correction approaches, the new code also maintains a comparatively low hardware complexity, marking a significant advancement toward scalable fault-tolerant quantum computing. Quantum error correction remains one of the defining challenges in the race toward practical quantum computing. Errors introduced by noise must be corrected faster than they accumulate, a requirement that previo
Estonia Raises the Bar for Secure Digital Identity in Europe With New eID Cards Developed With Thales9.6.2026 09:00:00 CEST | Press release
The Estonian Police and Border Guard Board has begun the issuance of the country’s new electronic identity (eID) cards, marking a major milestone in the ongoing modernisation of Estonia’s renowned digital identity programme. This new generation of cards has been developed in partnership with Thales under an eight-year contract covering the full lifecycle of national identity documents - from issuance to personalisation -for residents, citizens, and specific groups such as diplomats or refugees. The advanced eID cards1 feature cutting-edge embedded security elements that can be upgraded to counter emerging cyber threats, ensuring citizens’ digital transactions remain protected over time. With increasing cyber risks and the rapid evolution of digital public services, Estonia is reinforcing the security, durability and adaptability of the documents that underpin its digital society: identity cards, residence permit cards, e-resident digital identity cards, diplomatic identity cards, certi
Longpoint Expands into Germany and the Netherlands, Targeting €400 Million of Infill Logistics Investment9.6.2026 09:00:00 CEST | Press release
Firm appoints Gijs Vissers and Benedict Stichel as country heads to lead growth across two key European logistics markets Longpoint Partners today announced its expansion into Germany and the Netherlands, extending its infill industrial strategy into two of Europe’s most supply-constrained logistics markets. The firm is establishing a presence in high-demand locations, including Düsseldorf, Frankfurt, and the Randstad, and plans to deploy approximately €400 million into logistics assets near major population centers and transportation corridors. “We are excited to expand Longpoint’s infill industrial strategy into Germany and the Netherlands,” said Dwight Angelini, Founding and Managing Partner of Longpoint Partners. “These are highly attractive logistics markets with strong fundamentals, limited supply, and a clear need for high-quality light industrial and logistics space. With Gijs and Benedict leading our local efforts, we have the market knowledge, relationships, and discipline to
ISO/TC 251 Recognizes Ampowr as the Only BESS Operator With a Fully Integrated ISO Stack9.6.2026 09:00:00 CEST | Press release
ISO/TC 251 and NEN, the Netherlands national standards body, profile Ampowr alongside Rijkswaterstaat, the US Army Corps of Engineers, Novo Nordisk and Veolia after an in-depth methodology interview with Executive Director Andrew Elwell. ISO/TC 251, the international technical committee that authors the ISO 55000 family of asset management standards, has published a case study profiling Ampowr's integrated certification methodology. Authored by NEN, the Dutch national standards body, the study is now publicly available in the ISO/TC 251 case studies library alongside profiles of Rijkswaterstaat, the US Army Corps of Engineers, Novo Nordisk, and Veolia. ISO/TC 251 approached Ampowr directly. NEN subsequently conducted an in-depth interview with Executive Director Andrew Elwell, examining how Ampowr operates its five certifications (ISO 9001, ISO 14001, ISO 45001, ISO 27001 and ISO 55001), as a single integrated system rather than separate compliance silos. "To our knowledge we are the o
Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s9.6.2026 08:00:00 CEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced today that the Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s who have a pathogenic variant in the GBA1 gene (GBA-PD) did not meet its primary, nor the key secondary efficacy endpoints, meaning that BIA 28-6156 failed to slow the progression of GBA-PD versus placebo. BIA 28-6156 proved to be generally well tolerated in the study, with no unexpected safety concerns arising. While the study data provide valuable scientific information and contribute to a broader understanding of Parkinson’s biology, BIA 28-6156 did not demonstrate significant differentiation from placebo on the primary or key secondary endpoints measured. Based on the lack of demonstrated efficacy in this study, Bial has made the decision to discontinue further development of BIA 28-6156 for this indication. “We are disappointed with the outcome of the Phase 2b ACTIVATE study, as th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom